Maia Biotechnology Unveils Breakthrough Telomere-Targeting Therapy for Resistant Lung Cancer

Reuters12-11

Maia Biotechnology Unveils Breakthrough Telomere-Targeting Therapy for Resistant Lung Cancer

Maia Biotechnology Inc. announced promising scientific developments for its lead candidate, ateganosine, a telomere-targeting agent designed for patients with advanced non-small cell lung cancer (NSCLC) who are resistant to current immunotherapies and chemotherapies. The company highlighted that ateganosine's dual mechanism targets telomeres to directly induce cancer cell death while also stimulating the immune system's response. Maia recently received Fast Track Designation from the U.S. FDA for ateganosine in this patient population and is initiating the Phase 3 THIO-104 trial. The company also noted that ateganosine holds FDA Orphan Drug Designations for glioblastoma and hepatocellular carcinoma. Research results and further data will be presented in the future as the clinical trial progresses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9600216-en) on December 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590324095?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 03:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590324095","market":"nz","top_or_hot":-1,"title":"Maia Biotechnology Unveils Breakthrough Telomere-Targeting Therapy for Resistant Lung Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Maia Biotechnology Unveils Breakthrough Telomere-Targeting Therapy for Resistant Lung Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Maia Biotechnology Inc. announced promising scientific developments for its lead candidate, ateganosine, a telomere-targeting agent designed for patients with advanced non-small cell lung cancer (NSCLC) who are resistant to current immunotherapies and chemotherapies. The company highlighted that ateganosine's dual mechanism targets telomeres to directly induce cancer cell death while also stimulating the immune system's response. Maia recently received <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation from the U.S. FDA for ateganosine in this patient population and is initiating the Phase 3 THIO-104 trial. The company also noted that ateganosine holds FDA Orphan Drug Designations for glioblastoma and hepatocellular carcinoma. Research results and further data will be presented in the future as the clinical trial progresses.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9600216-en) on December 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Maia Biotechnology Unveils Breakthrough Telomere-Targeting Therapy for Resistant Lung Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaia Biotechnology Unveils Breakthrough Telomere-Targeting Therapy for Resistant Lung Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-11 03:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Maia Biotechnology Unveils Breakthrough Telomere-Targeting Therapy for Resistant Lung Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Maia Biotechnology Inc. announced promising scientific developments for its lead candidate, ateganosine, a telomere-targeting agent designed for patients with advanced non-small cell lung cancer (NSCLC) who are resistant to current immunotherapies and chemotherapies. The company highlighted that ateganosine's dual mechanism targets telomeres to directly induce cancer cell death while also stimulating the immune system's response. Maia recently received <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation from the U.S. FDA for ateganosine in this patient population and is initiating the Phase 3 THIO-104 trial. The company also noted that ateganosine holds FDA Orphan Drug Designations for glioblastoma and hepatocellular carcinoma. Research results and further data will be presented in the future as the clinical trial progresses.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9600216-en) on December 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014013.SGD","symbol_name":"United Global Durable Equities Fund Dis SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDLc6fPHz:1","article_id":"2590324095","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590324095","pubTimestamp":1765393212,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Maia Biotechnology Inc. announced promising scientific developments for its lead candidate, ateganosine, a telomere-targeting agent designed for patients with advanced non-small cell lung cancer  who are resistant to current immunotherapies and chemotherapies. The company highlighted that ateganosine's dual mechanism targets telomeres to directly induce cancer cell death while also stimulating the immune system's response. Maia recently received Fast Track Designation from the U.S. FDA for ateganosine in this patient population and is initiating the Phase 3 THIO-104 trial. The company also noted that ateganosine holds FDA Orphan Drug Designations for glioblastoma and hepatocellular carcinoma. Research results and further data will be presented in the future as the clinical trial progresses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is f","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","MAIA":"MAIA Biotechnology Inc.","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","BK4585":"ETF&股票定投概念","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4112":"金融交易所和数据","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4139":"生物科技","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD"},"translate_title":"Maia Biotechnology推出针对耐药肺癌的突破性端粒靶向疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MAIA":0.9,"NDAQ":0.9},"content_text":"Maia Biotechnology Unveils Breakthrough Telomere-Targeting Therapy for Resistant Lung Cancer\n    \n\n        Maia Biotechnology Inc. announced promising scientific developments for its lead candidate, ateganosine, a telomere-targeting agent designed for patients with advanced non-small cell lung cancer (NSCLC) who are resistant to current immunotherapies and chemotherapies. The company highlighted that ateganosine's dual mechanism targets telomeres to directly induce cancer cell death while also stimulating the immune system's response. Maia recently received Fast Track Designation from the U.S. FDA for ateganosine in this patient population and is initiating the Phase 3 THIO-104 trial. The company also noted that ateganosine holds FDA Orphan Drug Designations for glioblastoma and hepatocellular carcinoma. Research results and further data will be presented in the future as the clinical trial progresses.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9600216-en) on December 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590324095","isCrawlerRequest":true}